Tolvaptan for Euvolemic and Hypervolemic Hyponatremia: A Narrative Review
DOI:
https://doi.org/10.55175/cdk.v51i12.1498Keywords:
Electrolyte imbalance, hyponatremia, tolvaptanAbstract
Hyponatremia is an electrolyte imbalance disorder commonly found in clinical practice. Hyponatremia is associated with significant mortality and morbidity. Tolvaptan is an orally administered V2 receptor antagonist drug capable of aquaresis without excreting electrolytes, thus increasing plasma sodium concentration. Results from clinical trials showed tolvaptan to be a relatively safe and effective treatment in euvolemia and hypervolemia hyponatremia.
Downloads
References
Bie P. Mechanisms of sodium balance: Total body sodium, surrogate variables, and renal sodium excretion. Am J Physiol-Regul Integr Comp Physiol. 2018 Nov 1;315(5):R945–62. DOI: 10.1152/ajpregu.00363.2017.
Buffington MA, Abreo K. Hyponatremia: A review. J Intensive Care Med. 2016;31(4):223–36. DOI: 10.1177/0885066614566794.
Yang S, Goldin M. Therapeutic advances in hyponatremia: Fluids, diuretics, vaptans, and more. Am J Ther. 2018;25(1):e67–72. DOI: 10.1097/MJT.0000000000000663.
Verbalis JG. Euvolemic hyponatremia secondary to the syndrome of inappropriate antidiuresis. In: Peri A, Thompson CJ, Verbalis JG, editors. Frontiers of hormone research [Internet]. 2019 [cited 2023 Dec 12]:p. 61–79. Available from: https://www.karger.com/Article/FullText/493238.
Wang S, Zhang X, Han T, Xie W, Li Y, Ma H, et al. Tolvaptan treatment improves survival of cirrhotic patients with ascites and hyponatremia. BMC Gastroenterol. 2018;18(1):137. DOI: 10.1186/s12876-018-0857-0.
Filippatos T, Elisaf M, Liamis G. Pharmacological management of hyponatremia. Expert Opin Pharmacother. 2018;19(12):1337–44. DOI:10.1080/14656566.2018.1504920.
Oya T, Sato J, Maezawa K, Shiba N, Takeda M, Momose Y. Efficacy and safety of tolvaptan in chronic heart failure. J Pharm Pract Res. 2022 Aug;52(4):303–10. DOI: 10.1002/jppr.1814.
Tzoulis P, Kaltsas G, Baldeweg SE, Bouloux PM, Grossman AB. Tolvaptan for the treatment of the syndrome of inappropriate antidiuresis (SIAD). Ther Adv Endocrinol Metab. 2023 Jan;14:204201882311733. DOI: 10.1177/20420188231173327.
Rangarajan B, Binoy V, Hingmire SS, Noronha V. Tolvaptan. South Asian J Cancer 2014;03(03):182–4. DOI: 10.4103/2278-330X.136811.
Ball SG, Iqbal Z. Diagnosis and treatment of hyponatraemia. Best Pract Res Clin Endocrinol Metab. 2016 Mar;30(2):161–73. DOI: 10.1016/j.beem.2015.12.001.
Warren AM, Grossmann M, Hoermann R, Zajac JD, Russell N. Tolvaptan versus fluid restriction in acutely hospitalised patients with moderate-profound hyponatraemia (TVFR-HypoNa): Design and implementation of an open-label randomised trial. Trials 2022;23(1):335. DOI: 10.1186/s13063-022-06237-5.
Bernal A, Zafra MA, Simon MJ, Mahia J. Sodium homeostasis, a balance necessary for life. Nutrients 2023;15(2):395. DOI: 10.3390/nu15020395.
Kasper DL, Hauser SL, Jameson JL, Fauci A, Longo DL, Loscalzo J. Harrison principle of internal medicine. 19th Ed. New York: McGrawHill Education; 2015.
Bankir L, Bichet DG, Morgenthaler NG. Vasopressin: Physiology, assessment and osmosensation. J Intern Med. 2017;282(4):284–97. DOI: 10.1111/joim.12645.
Park EJ, Kwon TH. A minireview on vasopressin-regulated aquaporin-2 in kidney collecting duct cells. Electrolytes Blood Press. 2015;13(1):1-6. DOI:10.5049/EBP.2015.13.1.1.
Sahay M, Sahay R. Hyponatremia: A practical approach. Indian J Endocrinol Metab. 2014;18(6):760-71. DOI: 10.4103/2230-8210.141320.
Giuliani C, Peri A. The use of vaptans in hyponatraemia. EMJ Nephrol. 2014;1:105–12.
Warren AM, Grossmann M, Christ-Crain M, Russell N. Syndrome of inappropriate antidiuresis: From pathophysiology to management. Endocr Rev. 2023;44(5):819–61. DOI: 10.1210/endrev/bnad010.
Braun MM, Barstow CH, Pyzocha NJ. Diagnosis and management of sodium disorders: Hyponatremia and hypernatremia. Am Fam Physician. 2015;91(5):299-307.
Castello LM, Baldrighi M, Panizza A, Bartoli E, Avanzi GC. Efficacy and safety of two different tolvaptan doses in the treatment of hyponatremia in the Emergency Department. Intern Emerg Med. 2017 Oct;12(7):993–1001.
Verbalis JG, Ellison H, Hobart M, Krasa H, Ouyang J, Czerwiec FS, et al. Tolvaptan and neurocognitive function in mild to moderate chroni chyponatremia: A randomized trial (INSIGHT). Am J Kidney Dis. 2016;67(6):893–901. DOI: 10.1053/j.ajkd.2015.12.024.
Salahudeen AK, Thajudeen B. Role of tolvaptan in the management of hyponatremia in patients with lung and other cancers: Current data and future perspectives. Cancer Manag Res. 2016;8:105–14. DOI: 10.2147/CMAR.S90169.
Bondanelli M, Aliberti L, Gagliardi I, Ambrosio MR, Zatelli MC. Long-term low-dose tolvaptan efficacy and safety in SIADH. Endocrine 2023;82(2):390–8. DOI: 10.1007/s12020-023-03457-w.
Isiktas Sayilar E, Ersoy A, Ayar Y, Aydin MF, Yavuz M. Effectiveness of Tolvaptan Treatment in Hyponatremic Patients. Turk J Intern Med. 2020 Apr 29;2(2):43–7. Isiktas Sayilar E, Ersoy A, Ayar Y, Aydin MF, Yavuz M. Effectiveness of tolvaptan treatment in hyponatremic patients. Turk J Intern Med.2020;2(2):43–7. DOI: 10.46310/tjim.706226.
Waring R. Tolvaptan, a selective oral vasopressin v2-receptor antagonist, for hyponatremia. N Engl J Med. 2006;355(20):2099–112. DOI: 10.1056/NEJMoa065181.
Martin-Grace J, Tomkins M, O’Reilly MW, Thompson CJ, Sherlock M. Approach to the patient: Hyponatremia and the syndrome of inappropriate antidiuresis (SIAD). J Clin Endocrinol Metab. 2022;107(8):2362–76. DOI: 10.1210/clinem/dgac245.
Dunlap ME, Hauptman PJ, Amin AN, Chase SL, Chiodo JA, Chiong JR, et al. Current management of hyponatremia in acute heart failure: A report from the hyponatremia registry for patients with euvolemic and hypervolemic hyponatremia (HN Registry). J Am Heart Assoc. 2017;6(8):e005261. DOI: 10.1161/JAHA.116.005261.
Ong A, Gittus M, Haley H, Harris T, Borrows S, Padmanabhan N, et al. UK Kidney association guidance commentary: Tolvaptan for ADPKD (an update) [Internet]. 2024. Available from: https://ukkidney.org/sites/renal.org/files/FINAL%20VERSION%20-%20UKKA%20Tolvaptan%20Commentary%20-%20March%202024.pdf.
Yamazaki Y, Shiraishi Y, Kohsaka S, Nagatomo Y, Fukuda K, Kohno T, et al. Temporal trends in tolvaptan use after revision of national heart failure guidelines in Japan. Sci Rep. 2021;11(1):19360. DOI: 10.1038/s41598-021-98173-8.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Terence Judian, Samuel Alexsander
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
